Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 42
- Registration Number
- NCT00571493
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 36
- Registration Number
- NCT00570180
- Locations
- 🇨🇦
Cross Cancer Institute 11560 University Ave, Edmonton, Alberta, Canada
🇨🇦Queen Elizabeth II Health Sciences Centre., Halifax, Nova Scotia, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT00568880
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning
- Conditions
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT00564200
- Locations
- 🇪🇸
H. de Jerez, Jerez de la Frontera, Spain
🇪🇸Instituto Catalán de Oncología, Barcelona, Spain
🇪🇸H. 12 de Octubre, Madrid, Spain
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT00560352
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇪🇸Local Institution, Salamanca, Spain
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT00555906
- Locations
- 🇺🇸
University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇺🇸Barnes-Jewish Hospital, St. Louis, Missouri, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00553644
- Locations
- 🇺🇸
Kaiser Permanente-Irvine, Irvine, California, United States
🇺🇸Kaiser Permanente-Riverside, Riverside, California, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00548717
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 31
- Registration Number
- NCT00547534
- Locations
- 🇺🇸
Cornell Wiell Medical College, New York, New York, United States
🇺🇸Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Rochester Medical Center (James P. Wilmot Cancer Center), Rochester, New York, United States
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 31
- Registration Number
- NCT00546780
- Locations
- 🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸Moores Ucsd Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.